Clinical Trial Results:
A Phase 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - a Phosphodiesterase Type 4 Inhibitor (PDE4i) Dermal Formulation – on Atopic Dermatitis Patients with Skin Lesions of Moderate Severity
Summary
|
|
EudraCT number |
2012-003000-12 |
Trial protocol |
DE |
Global end of trial date |
18 Mar 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Mar 2016
|
First version publication date |
05 Aug 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
ROF-DERM_203
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01856764 | ||
WHO universal trial number (UTN) |
U1111-1133-6455 | ||
Sponsors
|
|||
Sponsor organisation name |
Takeda
|
||
Sponsor organisation address |
One Takeda Parkway, Deerfield, Illinois, United States, 60015
|
||
Public contact |
Medical Director, Takeda, +1 877-825-3327, trialdisclosures@takeda.com
|
||
Scientific contact |
Medical Director, Takeda, +1 877-825-3327, trialdisclosures@takeda.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
24 Jun 2014
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
11 Mar 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
18 Mar 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective was to evaluate the efficacy of dermal 0.5% roflumilast cream formulation compared with vehicle on the reduction of atopic dermatitis (AD) lesions during 15 days of treatment in AD subjects with skin lesions of moderate severity, using the modified local SCORing Atopic Dermatitis (SCORAD) tool.
|
||
Protection of trial subjects |
This study was conducted with respect for the study subjects in accordance with the protocol, the ethical principles that have their origin in the Declaration of Helsinki, the International Conference on Harmonisation (ICH) E6 Good Clinical Practice (GCP) guidance, and all applicable local regulations. All study participants were required to read and sign an Informed Consent Form.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
10 Jun 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 40
|
||
Worldwide total number of subjects |
40
|
||
EEA total number of subjects |
40
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
40
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
Participants took part in the study at 3 centers in Germany from 10 June 2013 to 18 March 2014. | |||||||||
Pre-assignment
|
||||||||||
Screening details |
Participants with an historical diagnosis of Atopic Dermatitis were enrolled in 1 of 2 twice daily (BID) treatment groups. | |||||||||
Period 1
|
||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Double blind | |||||||||
Roles blinded |
Subject, Investigator | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
0.5% Roflumilast Cream | |||||||||
Arm description |
Roflumilast 0.5%, cream, topically, twice daily for up to 15 days. | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
0.5% Roflumilast Cream
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Ointment
|
|||||||||
Routes of administration |
Topical use
|
|||||||||
Dosage and administration details |
Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
|
|||||||||
Arm title
|
Vehicle Cream | |||||||||
Arm description |
Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days. | |||||||||
Arm type |
Placebo | |||||||||
Investigational medicinal product name |
0.5% Roflumilast Cream
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Ointment
|
|||||||||
Routes of administration |
Topical use
|
|||||||||
Dosage and administration details |
Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
|
|||||||||
Investigational medicinal product name |
Vehicle Cream
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Ointment
|
|||||||||
Routes of administration |
Topical use
|
|||||||||
Dosage and administration details |
Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.
|
|||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
0.5% Roflumilast Cream
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Roflumilast 0.5%, cream, topically, twice daily for up to 15 days. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Vehicle Cream
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full Analysis Set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All randomized subjects who received at least one application of any double-blind study medication.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
0.5% Roflumilast Cream
|
||
Reporting group description |
Roflumilast 0.5%, cream, topically, twice daily for up to 15 days. | ||
Reporting group title |
Vehicle Cream
|
||
Reporting group description |
Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days. | ||
Subject analysis set title |
Full Analysis Set
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
All randomized subjects who received at least one application of any double-blind study medication.
|
|
|||||||||||||
End point title |
Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD) | ||||||||||||
End point description |
Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/crusts, excoriations and lichenification scored on a 4 point scale, where 0=absent and 3=severe, with a total possible score of 15. Higher scores indicate greater severity.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline and Day 15
|
||||||||||||
|
|||||||||||||
Notes [1] - One subject in the 0.5% Roflumilast group was missing Day 15 data. |
|||||||||||||
Statistical analysis title |
Statistical analysis | ||||||||||||
Comparison groups |
0.5% Roflumilast Cream v Vehicle Cream
|
||||||||||||
Number of subjects included in analysis |
39
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority [2] | ||||||||||||
P-value |
= 0.276 [3] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LS Mean Difference | ||||||||||||
Point estimate |
-0.55
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-1.5542 | ||||||||||||
upper limit |
0.4574 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.496
|
||||||||||||
Notes [2] - This was an exploratory study designed to obtain preliminary information on the efficacy and safety of topical roflumilast for the treatment of AD. [3] - Mixed Model Repeated Measures (MMRM) Model: SCORAD change from baseline = treatment + visit + treatment by visit interaction + baseline SCORAD score. |
|
|||||||||||||
End point title |
Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values | ||||||||||||
End point description |
Diffusion of water through the skin is measured using a Tewameter. At each visit, 3 measurements are taken per treatment area (at 3 different areas of the target lesion). The TEWL value at each visit is the average of these measurements.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline and Day 15
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statiscal Analysis | ||||||||||||
Comparison groups |
0.5% Roflumilast Cream v Vehicle Cream
|
||||||||||||
Number of subjects included in analysis |
39
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority | ||||||||||||
P-value |
= 0.095 [4] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LS Mean Difference | ||||||||||||
Point estimate |
-5.91
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-12.9134 | ||||||||||||
upper limit |
1.0835 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
3.454
|
||||||||||||
Notes [4] - MMRM model: TEWL change from baseline = treatment + visit + treatment by visit interaction + baseline TEWL score. |
|
|||||||||||||
End point title |
Change From Baseline to Day 15 in Participants’ Assessment of Pruritus | ||||||||||||
End point description |
Severity of pruritus is assessed by the participants and recorded on a numeric scale ranging from 0 to 10, where 0 indicates the absence of the symptoms and 10 indicates the most severe symptoms.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline and Day 15
|
||||||||||||
|
|||||||||||||
Notes [5] - One subject in the 0.5% Roflumilast group was missing Day 15 data. |
|||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||
Comparison groups |
0.5% Roflumilast Cream v Vehicle Cream
|
||||||||||||
Number of subjects included in analysis |
39
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority | ||||||||||||
P-value |
= 0.013 [6] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LS Mean Difference | ||||||||||||
Point estimate |
-1.56
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-2.7656 | ||||||||||||
upper limit |
-0.3492 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.596
|
||||||||||||
Notes [6] - MMRM model: Assessment of Pruritus change from baseline = treatment + visit + treatment by visit interaction + baseline Assessment of Pruritus score. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From the time informed consent is signed through 7 days after the last dose of study drug (up to Day 22)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
The population consisted of all randomized participants. At each visit, investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
16.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
0.5% Roflumilast Cream
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Roflumilast 0.5%, cream, topically, twice daily for up to 15 days. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Vehicle Cream
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
21 Nov 2012 |
Protocol Amendment 1
The following changes were implemented in Protocol Amendment 1:
• Changed department name for SAE and pregnancy reporting.
• Changed the signatory responsibility for pharmacovigilance and clinical trial management.
• Clarified contraception duration.
• Clarified that subjects not capable of giving informed consent were not allowed to participate in the study.
• Clarified that subjects with a history of regulator antidepressant administration would not be included.
• Added language to exclude institutionalized subjects.
• Added text to clarify that antidepressant use was excluded during the study.
• Lowered the threshold value for withdrawing subjects due to LFT abnormalities.
• Increased total volume of blood drawn due to extra clinical laboratory tests at Day 8.
• Clarified laboratory analysis and the use of a central laboratory.
• Clarified pregnancy and SAE reporting process.
• Corrected typographical errors.
|
||
15 Mar 2013 |
Protocol Amendment 2
The following changes were implemented in Protocol Amendment 2:
• Changed the sponsor name.
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |